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Aldosterone is one of a number of hormones that can be detrimental to myocardium, and whose circulating levels are elevated in chronic heart failure (HF). It contributes significantly to HF progression after myocardial infarction (MI) and to the morbidity and mortality of the disease (1-3). Aldosterone`s main actions on the post-MI heart include (but are not limited to) cardiac hypertrophy, fibrosis, and increased inflammation and oxidative stress, all of which result in adverse cardiac remodeling and progressive loss of cardiac function and performance (2) (3) (4) .
Aldosterone is a mineralocorticoid produced and secreted by the cells of the zona glomerulosa of the adrenal cortex in response to either elevated serum potassium levels or to angiotensin II (AngII) acting through its type 1A receptors (AT 1A Rs), which are endogenously expressed in the adrenocortical zona glomerulosa (AZG) cells (5, 6) . AT 1 Rs belong to the superfamily of 7-transmembrane spanning G-protein coupled receptors (GPCRs), and, upon agonist activation, couple to the G q/11 family of G-proteins (6) . Over the past few years however, a number of GPCRs, including the AT 1 R, have been shown to also signal through G proteinindependent pathways. The protein scaffolding actions of β-arrestin-1 and -2 (βarr1 and -2, also known as arrestins -2 and -3, respectively), originally discovered as terminators of GPCR signaling following phosphorylation of these receptors by the GPCR kinases (GRKs), play a central role in mediating G protein-independent signal transduction by these receptors (7, 8) .
We recently reported that adrenal GRK2, the major co-factor of βarr action toward receptors, is upregulated in HF leading, through its concerted action with βarr1, to increased desensitization/down-regulation of α 2 -adrenoceptors, and this mediates the increased adrenal catecholamine output seen in HF (9) . Since adrenal aldosterone production stimulated by AngII is increased in HF (1) (2) (3) , and βarr1 also regulates AT 1 R signaling (7, 8) , we hypothesized that order to test this in vitro, we used the human AZG cell line H295R, which endogenously expresses the AT 1 R, but not the AT 2 R (the other AngII receptor type). Importantly, these cells produce and secrete aldosterone in response to AngII stimulation (10, 11) . To examine whether adrenal βarr1 influences aldosterone turnover in vivo, we used our previously developed methodology for adrenal-targeted, adenoviral-mediated gene transfer (9, 12) of wild-type fulllength βarr1 in normal rats. We have uncovered a novel signaling pathway mediated by βarr1 that leads to aldosterone production by the AT 1 R in AZG cells in vitro, which, importantly, is also operative in vivo, since adrenal βarr1 overexpression was found to be capable of increasing circulating levels of aldosterone in vivo.
Results β β β βarr1-mediated AngII-induced aldosterone production in vitro. Since AngII is known to promote aldosterone production in AZG cells, we set out to explore a potential role for βarrs in this effect. In H295R cells, treatment with 10 nM AngII leads to a significant induction of aldosterone secretion, as expected (Fig. 1A) . Western blotting with an antibody against both βarr isoforms in native extracts from these cells revealed that only βarr1 is expressed endogenously in significant amounts (Fig. 1B) . Consistent with this, human adrenal glands express βarr1 robustly (SI Fig. 1 ), and importantly, βarr1 co-localizes with the known adrenocortical protein, steroidogenic acute regulatory protein (StAR), in human adrenocortical sections (Fig. 1C) .
Aldosterone synthesis in AZG cells is initiated by the mitochondrial uptake of cholesterol, the precursor of all adrenal steroids (10) . Mitochondrial cholesterol uptake is the rate-limiting step of this procedure and is catalyzed by the steroid transport protein StAR, whose levels are upregulated in response to AngII stimulation (10, 13) . Consistent with this, we observed a large StAR upregulation in H295R cells 6 hrs post-AngII stimulation (Fig. 1B) .
In order to test whether endogenous βarr1 plays a role in AngII-induced aldosterone production/secretion, we transfected H295R cells with the V53D dominant negative βarr1 mutant (DN βarr1), which prevents βarr1 from interacting with its various intracellular nonreceptor binding partners (14, 15) . As shown in Fig. 1D , DN βarr1 overexpression led to marked inhibition of AngII-induced aldosterone secretion, compared to control empty vector (EV)-transfected cells. In addition, the AngII-induced StAR upregulation normally observed in EVtransfected cells was also absent in DN βarr1-transfected cells (Fig. 1E) . Conversely, transfection of H295R cells with an adenovirus encoding for wild-type βarr1 (Adβarr1) led to significantly enhanced AngII-induced aldosterone secretion compared to control AdGFP (Green Fluorescent Protein)-transfected cells (Fig. 1F) , which was also accompanied by a marked enhancement of AngII-induced StAR upregulation (Fig. 1G) . Taken together, these results show that βarr1 is necessary for AngII-induced StAR upregulation and subsequent aldosterone production in AZG cells in vitro. β β β βarr1-mediated AT 1 R signaling to aldosterone production involves DAG and sustained
ERK activation.
To further dissect the signaling pathway of AngII-induced aldosterone production mediated by βarr1 in AZG cells, we focused on βarr1-promoted ERK1/2 activation. ERK1/2 play a central role in StAR upregulation by means of inducing StAR gene transcription in response to AngII stimulation in AZG cells (13) . βarrs have been shown to mediate AT 1 R signaling to ERKs in various heterologous cell systems in vitro (7, 8) . Following AngII stimulation for various times, we found that βarr1 overexpression does lead to sustained AngII-induced ERK1/2 activation in Recently, βarr1 was shown to recruit the diacylglycerol (DAG) kinases (DGKs) to activated M 1 muscarinic cholinergic receptors, which also couple to Gq-proteins like the AT 1 Rs, thereby catalyzing the conversion of the Gq-dependent second messenger DAG to phosphatidic acid (PA) at the cell membrane (16) . PA is a potent ERK cascade activator by means of bringing together Ras and Raf1 kinase at the level of the plasma membrane to interact with each other (17) . Therefore, we hypothesized that this βarr1-mediated mechanism could be at play in AngIIinduced sustained ERK1/2 activation in AZG cells, as well. To test this, we pretreated transfected H295R cells with the phospholipase C (PLC) inhibitor U73122 (18) to suppress all DAG production before AngII stimulation. In the presence of PLC inhibition, βarr1 β β β βarr1 mediates aldosterone production in vivo. Next, we examined whether adrenal βarr1 can affect aldosterone production in vivo, as well. Adrenal gland-specific overexpression of βarr1 in normal rats via infection with Adβarr1 in vivo led to a significant increase in plasma aldosterone levels compared to control AdGFP rats (536+50 pg/ml vs. 235+40 pg/ml, respectively, n=5, p<0.01) (Fig. 4A ) at seven days post-in vivo gene delivery. βarr1 was markedly overexpressed in the adrenals of Adβarr1 rats (Fig. 4B ).
Since GRK2 is a co-factor of βarr1 activity towards receptors, we also delivered an adenovirus carrying GRK2 (AdGRK2) to normal rat adrenal glands. As shown in Fig. 4A, GRK2 overexpression resulted in a small but significant increase in plasma aldosterone at 7 days postgene delivery compared to control AdGFP-treated rats (322+20 pg/ml, n=5, p<0.05 vs. AdGFP),
indicating that increased activity/expression of GRK2 in the adrenal gland increases aldosterone production, as well. This is consistent with induced βarr1 acting at the plasma membrane. 
Discussion
Over the past few years, a novel role for βarr1 and -2, molecules initially discovered as terminators of G protein signaling by GPCRs, has emerged, i.e. that these two proteins, after uncoupling the activated receptor from its cognate G-protein, actually serve as signal transducers for the receptor in their own right (7, 8) . However, this novel role of βarrs has thus far been demonstrated almost exclusively in heterologous cell systems in vitro. The present study delineates a novel signaling pathway mediated by βarr1, which operates in vitro and in vivo, in a specialized cell type/tissue (ZG cells of the adrenal cortex), and which leads to an important physiological effect (AngII-induced aldosterone production). Moreover, this increased aldosterone production may then precipitate diseases that are characterized and aggravated by enhanced circulating levels of this hormone, such as post-MI HF progression (3, 4) .
Additionally, our data strongly suggest that blocking adrenal βarr1 actions on AT 1 R might serve as a novel therapeutic strategy for lowering aldosterone levels in pathological conditions characterized and precipitated by elevated aldosterone levels, one of the most important of which is post-MI progression to HF. Testing the effects of adrenal βarr1 inhibition in vivo in post-MI HF in order to validate this important receptor regulatory protein as a novel therapeutic target in HF will be the focus of our next study.
Suppression of aldosterone production at its various sources, the most important of which physiologically is the adrenal cortex, is of particular importance, since aldosterone has been shown to exert some of its actions (its so-called "non-genomic" actions) by binding other molecular targets than the mineralocorticoid receptor (MR), the molecular target that normally mediates its cellular actions (2,3). These MR-independent actions are of course unaffected by the currently available MR antagonist drugs, such as eplerenone and spironolactone, used in the treatment of HF. Therefore, curbing aldosterone production at its major source, i.e. the adrenal cortex, by inhibiting βarr1 actions, could presumably be more effective therapeutically than inhibiting its actions at its receptor level and we are planning to investigate this in an in vivo experimental model of HF.
The pathway of βarr1-dependent AT 1 R signaling to aldosterone production appears to be initiated by the recruitment of βarr1 to the activated AT 1 R which scaffolds DGK(s) to the Although AT 1 R has been shown to result in sustained ERK activation via βarrs, it is the βarr2 isoform that has actually been shown to mediate this effect, whereas βarr1 has actually been shown to act in the opposite direction, i.e. rather inhibiting AT 1 R-induced ERK activation (22) . Recently, it was shown in transfected HEK293 cells that βarr1 only inhibits AT 1 R signaling to ERK by classically desensitizing the receptor (i.e. uncoupling it from the G protein), and βarr2
instead promotes the G protein-independent signaling of AT 1 R to ERKs, but this βarr2-mediated ERK activation produces no transcriptional effects (23) . Our present findings seem to be in discordance with these studies. However, it should be emphasized here that these studies were 13 done in transfected heterologous systems, with overexpressed receptors at supra-physiological levels, and also with recombinant (not natural) AT 1 Rs engineered in such a way that they cannot couple to any G proteins. Given that signaling from a given GPCR to ERKs can vary widely depending on the relative concentrations of receptor, G-proteins, GRKs, and βarrs, as well as on the cellular context in general (i.e. cell type and cellular signaling machinery) (8, 23) , this apparent discrepancy can be easily explained. Additionally, the H295R cells used in the present study do not express significant amounts of βarr2 endogenously, so βarr2 is unlikely to be involved in AngII-induced aldosterone production, at least in this system (see Figure 1B) .
Nevertheless, it is entirely plausible that βarr2 might have different or even opposite effects on the signaling pathway leading from AT 1 R activation to aldosterone production in other AZG cell lines or in vivo, and this is going to be the focus of future studies.
βarr-activated ERKs have been shown to be largely retained in the cytosol due to their association with receptor-arrestin complexes, and thus not to be able to translocate to the nucleus to induce transcriptional effects (22, 23) . However, βarr1 localizes in the cytoplasm, as well as in the nucleus by virtue of possessing a nuclear localization sequence, whereas βarr2 is excluded from the nucleus due to a nuclear export sequence present in its molecule (24) . In fact, βarr1
translocates into the nucleus in response to stimulation of the µ-opioid receptor, a G i/o -coupled receptor, wherein it interacts with the p27 and c-Fos promoters and stimulates transcription by recruiting histone acetyltransferase p300 and enhancing local histone H4 acetylation (25, 26) . On the other hand, ERK1/2 not only target nuclear transcription factors, but also numerous other plasma membrane, cytoplasmic, and cytoskeletal substrates (27) , some of which mediate the reportedly non-transcriptional effects of βarr-activated ERKs, such as chemotactic T-and B-cell migration (28, 29) . Some other ERK substrates though, such as the Rsk and Mnk protein kinases, can translocate to the nucleus and activate transcription factors, thereby producing the transcriptional effects of activated ERK1/2 indirectly (27) . Indeed, the cardiac-specific overexpression of a G protein-uncoupled mutant AT 1 R has been reported, which induces ERK1/2 activation that promotes a histologically distinct form of cardiac hypertrophy from that caused by the wild type receptor, with greater cardiomyocyte hypertrophy and less cardiac fibrosis (30) . This suggests that ERK1/2 activated independently of G proteins can produce The final important finding of the present study is that SII can completely recapitulate the AngII effects on aldosterone production, albeit at significantly lower concentrations, consistent with its lower potency at AT 1 R compared to the physiological full agonist AngII. This finding has enormous pharmacological and therapeutic ramifications, since it strongly argues for the existence of at least two different active conformations of the AT 1 R, one of which would lead only to βarr1 but not G-protein activation, but which both result in aldosterone production in 15 AZG cells. Therefore, complete blockade of both of these conformations would be warranted in order to achieve the most effective suppression of AngII-dependent aldosterone production. To our knowledge, the relative efficacy of the currently available AT 1 R antagonist drugs (the sartans) at inhibiting these two signaling pathways emanating from AT 1 R (i.e. the G protein-and the βarr-mediated) has never been tested and is completely unknown and thus will also be the focus of our future studies. In fact, there have been several reports of limited efficacy of some AT 1 R antagonists at suppressing aldosterone in HF (32-34), despite their more or less equal capability to inhibit G-protein activation by the AT 1 R. It would thus be interesting to examine whether variations in the efficacy of these agents at inhibiting AT 1 R−βarr coupling could account for their reduced efficacy at suppressing aldosterone. Based on the results of the present study however, the most effective AT 1 R antagonist at inhibiting AngII-dependent aldosterone production should be an agent that would inhibit both AT 1 R-G protein and AT 1 R-βarr1 coupling equally well.
In conclusion, the present study reports a novel, G protein-independent signaling pathway mediated by βarr1 in adrenocortical zona glomerulosa cells that underlies aldosterone production in response to AngII in vitro and in vivo. Activity of this pathway appears to regulate adrenal aldosterone production, and hence circulating levels of this mineralocorticoid in vivo. Thus, adrenal βarr1 activity towards the AT 1 R might represent a novel therapeutic target for reducing plasma aldosterone levels in pathological conditions where this is desirable, including several endocrinological disorders characterized by hyperaldosteronism and cardiovascular disease. In vivo adrenal gene delivery in normal rats. All animal procedures and experiments were performed in accordance with the guidelines of the IACUC of Thomas Jefferson University.
Adrenal-specific in vivo gene delivery was done essentially as described (12), via direct delivery of adenovirus in the adrenal glands.
Construction and purification of adenoviruses. Recombinant adenoviruses that encode GRK2
(AdGRK2) or rat wild type, full length β-arrestin1 (Adβarr1) were constructed as described previously (9) . Briefly, transgenes were cloned into shuttle vector pAdTrack-CMV, which harbors a CMV-driven green fluorescent protein (GFP), to form the viral constructs by using standard cloning protocols. As control adenovirus, empty vector which expressed only GFP (AdGFP) was used. The resultant adenoviruses were purified, as described previously, using two sequential rounds of CsCl density gradient ultracentrifugation (9).
H295R cell culture and transfection. H295R cells were purchased from American Type
Culture Collection (Manassas, VA, USA) and cultured as previously described (35) . Transfection was performed either with Adβarr1 or AdGFP or with pcDNA3.1 plasmid encoding either for the V53D dominant negative βarr1 mutant (14) NC, USA), and GAPDH (MAB374; Chemicon, Temecula, CA, USA) were done using protein extracts from rat adrenal glands or in H295R cell extracts, as described previously (9).
Visualization of western blot signals was performed with Alexa Fluor 680-(Molecular Probes)
or IRDye 800CW-coupled (Rockland Inc.) secondary antibodies on a LI-COR infrared imager (Odyssey).
Co-immunofluorescence.
Immunofluorescence imaging of human adrenal cross-sections was carried out as described previously (9) . Briefly, human adrenal cross-sections were fixed, permeabilized and labeled with rabbit polyclonal anti-StAR (sc-25806) and goat anti-βarr1 (sc-9182; Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies, followed by the Steroidogenic Acute Regulatory protein.
